All Cases

Rare Disease

Developed a rare liver disease market landscape for an investment group looking to identify potential acquisition targets for an expansion to the U.S. market and performed commercial due diligence resulting in an acquisition of over $2B

Crafted a dynamic pricing model for a rare respiratory disease to evaluate channel- and account-specific pricing and contracting options

Identified emotional drivers influencing treatment selection at specific points in the patient journey for a rare disease

Identified and mapped KOLs and COEs, and assessed therapeutic approach and drivers of adoption to inform launch strategy for a mid-sized pharmaceutical company seeking to launch internationally

Built a geographic view of the treatment landscape for familial hypercholesterolemia to understand treatment adoption and inform our biotech client’s action plan and resourcing requirements

Identification of emerging market launch scenarios with highest success probability for a large pharmaceutical company 

Evaluated the global strategic launch plan and tailored it to fit the needs of the local marketplace, maximizing the patient pool touched by commercialization efforts

Identified expected penetration and uptake of a DMD therapy in EU-4 + UK using LSC center-based assessment (CBA) methodology to inform 5-year commercial forecast and dependent business decisions at a mid-sized European pharmaceutical company